Bryan Johnson, known for his high-profile biohacking, invested $2 million annually in anti-aging treatments including rapamycin. Despite promising early data, he experienced adverse effects like increased heart rate and cholesterol imbalances. His transparent recount on TheBioHack offers an instructive case study on the balance between experimental ambition and unexpected outcomes.
Q&A
- What triggered the adverse effects?
- How do epigenetic markers relate to the experiment?
- Why is transparency important in biohacking?